Tweenvest Stocks

BELLUS Health Inc. (TSX: BLU)

Health Care · Biotechnology · CA

CA$—

— today · — 1Y

BELLUS Health Inc. (TSX: BLU) operates in the Biotechnology industry within the Health Care sector.

Tweenvest scores BELLUS Health Inc. across four factors: quality 41/100, value 63/100, growth 0/100. Its strongest factor is value.

BLU price history

Not enough price history to draw a chart yet.

Key figures

Market cap
—
Revenue (TTM)
$15.00K
P/E
—
EPS
-0.72
Dividend yield
—
Beta (5Y)
—
52-week high
CA$—
52-week low
CA$—
Avg volume (3M)
—
Shares outstanding
—
Employees
74
Next earnings
—

About BELLUS Health Inc.

BELLUS Health Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to creating new therapeutic options for intractable chronic cough (RCC) and various other conditions characterized by heightened cough sensitivity. The company's primary investigational compound, BLU-5937, functions as a P2X3 receptor antagonist. This drug is currently progressing through Phase II clinical trials, where it is being assessed for its potential in treating both RCC and persistent itching. Founded in 1993, BELLUS Health Inc. is headquartered in Laval, Canada.

ISIN
CA07987C2040
Founded
1993
Listed since
Jun 22, 2000
Exchange
The Toronto Stock Exchange
Currency
CAD
CompanyMarket capPriceDay
PhaseRx, Inc.OTCPK: PZRX.Q$12.00$——
ContraFect CorporationOTCPK: CFRX.Q$11.00$0.00—
Notable Labs, Ltd.OTCPK: NTBL.Q$10.00$——
OncoSec Medical IncorporatedOTCPK: ONCS.Q$6.00$0.00—
Calithera Biosciences, Inc.OTCPK: CALA$5.00$0.00-99.00%
Biocept, Inc.OTCPK: BIOC.Q$3.00$0.00-99.50%
Yield10 Bioscience, Inc.OTCPK: YTEN.Q$1.00$——
LadRx CorporationOTCPK: LADX$0.00$0.00-99.50%

Browse every Biotechnology company →

Figures last refreshed Oct 18, 2026.